SystImmune Inc. products

SystImmune - Model SI-B001 - Specificity Enhanced Bi-specific Antibody (SEBA)

This Specificity Enhanced Bi-specific Antibody (SEBA) is of the oncology therapeutic class that bind functional proteins on the surface of cells, in this molecule to block growth signals that cancer cells depend on for survival. The SEBA technology allows the molecule to use one surface protein for specific targeting of the cancer, and a then block a second protein, even if it is not specific for the cancer. ‍The bi-specific SEBA SI-B001 is built on a tetravalent platform having two binding domains for distinct Growth Factor Receptors that drive cancer cell proliferation and survival. The SI-B001 primary mechanism of action is the blocking of EGFR and HER3 signals to cancer cells, and secondarily, through a wt FC receptor mediating innate immune effector functions toward the cancer cells. SI-B001 is currently being evaluated as a single agent in clinical trials enrolling patients with a variety of solid tumor indications.

SystImmune - Model SI-B003 - Tetravalent

By combining bi-valency with bi-specificity in the tetravalent format, the dual checkpoint molecule utilizes avidity and bi-specificity to improve anti-cancer immune cell function. The specificity enhancement both synergistically enhance and expand the breadth of immune cell activity that is diminished in cancer patients (SEBA). The spatio-temporal control of bi-specificity ensure that synergistic blocking of inhibitory receptors is happening in the right place for greatest effect. The tetravalent SI-B003 has two binding domains for T cell checkpoint axis, PD-1 and CTLA-4. The primary targets for this molecule are exhausted tumor-specific T cells which demonstrate enhanced functionality upon treatment with PD-1 and CTLA-4 blocking antibodies, restoring their anti-tumor activity. SI-B003 is currently being evaluated as a single agent in clinical trials enrolling patients with a variety of solid tumor indications.

SystImmune - Model GNC-038 - Guidance and Navigation Control (GNC) Molecules

Guidance and Navigation Control (GNC) molecules are multi-specific cell engager proteins. GNC in the oncology therapeutics class bind to cancer cells and to immune cells and stimulate the immune cell cancer killing activity. By design, each GNC molecule is multi-function. In the process of killing, the GNC is designed to educate and empower the T cells to be more effective at killing cancer.

SystImmune - Model GNC-035 - Guidance and Navigation Control (GNC) Molecules

SystImmune - Model GNC-039 - Guidance and Navigation Control (GNC) Molecules

SystImmune - Model BL-B01D1-ADC - Specificity Enhanced Bi-specific Antibody (SEBA) Molecules

Built on the foundation of Specificity Enhanced Bi-specific Antibody (SEBA) molecules the SEBA-ADC have an advanced mechanism of action. This advanced functional class is referred to as Heterogeneity overcoming - Immunogenic death inducing - Resistance antagonizing - Enhanced Specificity (HIRE) molecules that target cancer cells. While HIRE molecules provide cancer cells specific targeting, and exert bi-modal proliferative inhibition, any cancer cell clones attempting proliferative escape are exposed to topoisomerase inhibition and die when attempting to duplicate.

SystImmune - Model BL-M07D1-ADC - Antibody Drug Conjugates (ADC) Molecules

Antibody Drug Conjugates (ADC) molecules utilize specific antibodies to deliver therapeutic small molecules specifically to cancer cells. ADC are created in cooperation with Bai-Li Pharmaceutical’s R&D Center of Excellence and enable the development of sophisticated chemistries that give this class of drugs their therapeutic payload. This advanced functional class is referred to as Heterogeneity overcoming - Immunogenic death inducing - Resistance antagonizing - Enhanced Specificity (HIRE) molecules that target cancer cells.